109881 Aventis.
作者信息
Ojima Iwao, Geney Raphaël
机构信息
Department of Chemistry, Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA.
出版信息
Curr Opin Investig Drugs. 2003 Jun;4(6):737-40.
PMID:12901234
Abstract
109881 is an orally and intravenously active taxoid in development by Aventis Pharma (formerly Rhône-Poulenc Rorer) as a potential treatment for a variety of taxoid-resistant solid tumors, such as brain and lung cancers. As of April 2000, the compound was in phase IIa trials in the US, France, Belgium and Germany. Phase II trials were ongoing in May 2001, and the company was evaluating an oral formulation at this time.
摘要
Zotero 插件